Compare Ascendis Pharma A/S (ASND) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vipshop Holdings Ltd - ADR — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Vipshop Holdings Ltd - ADR trades at $15.06 (market cap $7.40B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.02% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VIPS | |
|---|---|---|
Market Cap | $16.78B | $7.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $20.68 |
52-Week Low | $189.74 | $12.92 |
Enterprise Value | $17.15B | $3.97B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
Vipshop Holdings (VIPS) trades at $15.68, up 1.75% with a bullish technical signal. The stock shows attractive valuation metrics including a P/E of 7.1 and P/S of 0.5, while maintaining solid profitability with 7.07% net margin and 18.43% ROE. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through outlet store strategies. Analyst consensus leans bullish with 53.57% buy ratings.
The outlook remains constructive given discounted valuation and operational efficiency, though revenue stagnation and competitive pressures in China's e-commerce sector present challenges. Positive cash flow generation and strategic initiatives support potential upside, but investors should monitor execution on growth initiatives amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
